Answers are grounded in this paper and cite their sources.
This study aims to explore the cost-effectiveness of atezolizumab plus bevacizumab against sorafenib for first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC) in Singapore.
No takes yet. Share an insight, caveat, or question.
Chee et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: